Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,240.0
5.5 (0.17%)

 

  • STI Straits Times Index
    3,240.0
    5.5 (0.17%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,574.4
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,940.5
    31.3 (0.11%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,827.2
    31.7 (0.13%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,244.1
    -5.1 (-0.08%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,246.1
    -21.1 (-0.93%)
    Index delayed 20 minutes
  • XAO XAO
    7,203.2
    4.2 (0.06%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 872.5M
  • Value: 729.0M
  • Rise: 113
  • Fall: 130
  • Unch: 575

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.104-0.001
ThaiBev0.795+0.005
Rex Intl0.181+0.007
Spackman0.018+0.002
Golden Agri-Res0.225-
Genting Sing0.910-0.005
Joyas Intl0.003-
OEL0.023-0.001
YZJ Shipbldg SGD1.040-0.020
AusGroup^0.042+0.003

World Indices

World Indices
Name Last Change
Nasdaq 9,402.5 +18.7
HSI 27,940.5 +31.3
HSCEI 10,969.3 +17.0
Jakarta 6,244.1 -5.1
Nikkei 225 23,827.2 +31.7
SSE Comp 2,976.5
Shanghai A 3,118.9
Shanghai B 248.6
PSE Comp 0.0
KOSPI 2,246.1 -21.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS AUTOLUS THERAPEUTICS PLC SPONSORED ADR
Updated on 23 Jan 2020 (End of trading day)
Last (USD): 9.990 Change: -2.480 High: 10.460 Remarks: -
Change (%): -19.89 Low: 9.700
Open 10.000 Yesterday's Close 12.47
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,869,464 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.99815 Trailing EPS (USD) e -0.99815 NAV (USD) b 5.9951
PE a - Trailing PE f - Price / NAV b 1.6664
Dividend (USD) d - Cash In Hand (USD) g 5.1148 Issued & Paid-up Shares c 52,232,400
Dividend Yield (%) d - Price / Cash In Hand g 1.953 Treasury Shares h -
Beta - 75 Daysi -0.114 R-Squared - 75 Days(%)i - Market Cap (M) 521.802
Beta - 500 Daysi 0.525 R-Squared - 500 Days (%)i 1.22 Enterprise Value (M) 318.444
Piotroski F Score 2 Exchange Code AUTL Par Value ( $ ) n.a.
52 Weeks Volatility (%) 71.54 Free Float (%) 86.0
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 23 Jan 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 14 Jun 2018.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS NASDAQ 521.802 - - 1.6664 -
Industry Biotechnology NASDAQ 2,388.271 378.262 92.382 5.9502 0.740
Local Peer AMGEN INC NASDAQ 139,657.007 16.638 17.312 12.7809 2.380
Local Peer GILEAD SCIENCES INC NASDAQ 80,893.691 14.829 30.039 3.9261 3.613
Local Peer VERTEX PHARMACEUTICAL NASDAQ 60,149.957 28.692 28.058 11.4497 -
Local Peer BIOGEN INC NASDAQ 51,283.421 11.575 9.505 3.6642 -
Local Peer ILLUMINA INC NASDAQ 48,069.000 58.195 49.403 10.8288 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 39,153.243 16.018 18.260 3.7273 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 24,021.138 309.550 16.338 2.3170 -
Local Peer SEATTLE GENETICS INC NASDAQ 19,769.375 - - 11.1089 -
Local Peer INCYTE CORPORATION NASDAQ 16,852.661 153.916 41.615 6.9566 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,381.289 - - 5.0030 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 15,009.211 - 48.361 5.4303 -
Local Peer EXACT SCIENCES CORP NASDAQ 13,571.846 - - 18.1375 -
Other Local Peers ALNYLAM PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), 10X GENOMICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), FIBROGEN INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), EPIZYME INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), VIELA BIO INC (NASDAQ), INSMED INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), ALECTOR INC (NASDAQ), CORTEXYME INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), DERMIRA INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), XBIOTECH INC (NASDAQ), INTREXON CORP (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), OMEROS CORP (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), RETROPHIN INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), NANTKWEST INC (NASDAQ), AVROBIO INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), ARDELYX INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MACROGENICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AGENUS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), BELLUS HEALTH INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CABALETTA BIO INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CUE BIOPHARMA INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), GERON CORP (NASDAQ), KAMADA (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), SERES THERAPEUTICS (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), AFFIMED N V (NASDAQ), IMV INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), ATHERSYS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), XOMA CORP (NASDAQ), CHIASMA INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), VERASTEM INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), SAVARA INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ADURO BIOTECH INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), COHBAR INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), OTONOMY INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), SYNLOGIC INC (NASDAQ), ORGENESIS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), TREVENA INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), VACCINEX INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), EQUILLIUM INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SOLIGENIX INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), CURIS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), INMUNE BIO INC (NASDAQ), RESTORBIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), ZAFGEN INC (NASDAQ), EVOGENE LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), OCUGEN INC (NASDAQ), BIOCARDIA INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), BIONANO GENOMICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), VAXART INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), PRECIPIO INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), BIOCEPT INC (NASDAQ), TOCAGEN INC (NASDAQ), TROVAGENE INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), SENESTECH INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), OPGEN INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 141,021.137 52.562 52.563 18.8452 0.854
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,628.000 87.431 25.796 5.8189 0.686
Global Peer SINO BIOPHARM HKEx 143,847.408 13.425 13.933 4.2839 0.640
Global Peer WUXI BIO HKEx 134,349.414 179.875 140.620 13.8295 -
Global Peer BEIGENE HKEx 100,670.850 - - 10.0445 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 33,091.696 199.005 - 9.3319 -
Global Peer 3SBIO HKEx 27,939.670 18.469 22.480 2.7538 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,999.871 47.845 697.644 2.8984 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), FRONTAGE (HKEx), CKLIFE SCIENCES (HKEx), AVITA MEDICAL LTD (ASX), VIVA BIOTECH (HKEx), KADMON HLDGS INC (NYSE), ASCENTAGE-B (HKEx), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), NANOVIRICIDES INC (NYSE American), LEE'S PHARM (HKEx), DPHARMA (Bursa), NEXT SCIENCE LTD (ASX), PFENEX INC (NYSE American), TELIX PHARMACEUTIC (ASX), BBI LIFE SCI (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), CEL-SCI CORP (NYSE American), PYC THERAPEUTICS LIMITED (ASX), UNI-BIO GROUP (HKEx), RESAPP HEALTH LIMITED (ASX), ENZO BIOCHEM INC (NYSE), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), IMUGENE LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ONCOSIL MEDICAL LIMITED (ASX), ORTHOCELL LIMITED (ASX), CT ENTERPRISE (HKEx), ISORAY INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), BIOTRON (ASX), GENETIC TECHNOLOGIES (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ANTEOTECH LIMITED (ASX), ACTINOGEN MEDICAL LTD (ASX), BIONOMICS LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), MEMPHASYS LTD (ASX), IBIO INC (NYSE American), REGENT PACIFIC (HKEx), TALI DIGITAL LIMITED (ASX), ORAGENICS INC (NYSE American), CCP TECHNOLOGIES LTD (ASX), EXTRAWELL PHAR (HKEx), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), REGENEUS LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), ADALTA LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), AIM IMMUNOTECH INC (NYSE American), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), QT Vascular (SGX), LIVING CELL TECHNOLOGIES (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), HAO WEN HLDGS (HKEx), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), MGRC (Bursa), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --2.560
-20.40 %
10 Days --2.570
-20.46 %
20 Days --3.620
-26.60 %
Medium Term Return 3 Months --3.420
-25.50 %
6 Months --3.760
-27.35 %
1 Year --16.010
-61.58 %
Annualised Return Annualised --
-61.58 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 9.500 - 32.844 Change From 1 Year Low +0.490 % Change From 1 Year Low (%) +5.16
Change From 1 Year High -22.854 % Change From 1 Year High (%) -69.58
2 Years Range 9.500 - 53.240 Change From 2 Years Low +0.490 % Change From 2 Years Low (%) +5.16
Change From 2 Years High -43.250 % Change From 2 Years High (%) -81.24
5 Years Range 9.500 - 53.240 Change From 5 Years Low +0.490 % Change From 5 Years Low (%) +5.16
Change From 5 Years High -43.250 % Change From 5 Years High (%) -81.24
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Historical Price Data

Date Open High Low Close Volume VWAP
23 Jan 2020 10.000 10.460 9.700 9.990 1,869,464 -
22 Jan 2020 12.910 12.970 12.370 12.470 61,480 -
21 Jan 2020 12.560 12.910 12.270 12.840 73,782 -
17 Jan 2020 12.860 13.080 12.410 12.550 113,607 -
16 Jan 2020 12.690 13.120 12.670 12.850 112,133 -
15 Jan 2020 12.610 13.000 12.600 12.720 83,132 -
14 Jan 2020 12.510 13.100 12.470 12.700 107,634 -
13 Jan 2020 12.560 12.950 12.200 12.590 70,834 -
10 Jan 2020 12.780 13.240 12.500 12.560 109,308 -
09 Jan 2020 12.940 13.200 12.850 12.850 64,676 -
08 Jan 2020 12.840 13.194 12.730 13.000 111,680 -
07 Jan 2020 12.930 13.200 12.810 12.990 71,515 -
06 Jan 2020 12.750 13.100 12.628 12.940 82,226 -
03 Jan 2020 12.860 13.115 12.570 12.910 110,841 -
02 Jan 2020 13.100 13.770 12.500 12.960 55,417 -
31 Dec 2019 14.010 14.290 13.060 13.200 117,399 -
30 Dec 2019 13.610 14.190 13.540 14.090 134,246 -
27 Dec 2019 14.160 14.260 13.520 13.610 112,524 -
26 Dec 2019 14.310 14.670 13.850 14.190 66,560 -
24 Dec 2019 13.600 14.320 13.120 14.270 42,624 -
23 Dec 2019 12.790 13.790 12.320 13.560 94,047 -
20 Dec 2019 13.190 13.238 12.530 12.790 167,914 -
Summary
Current 2 Weeks
(09 Jan 2020 to 23 Jan 2020)
12.940 13.240 9.700 9.990 2,666,050 -
Previous 2 Weeks
(24 Dec 2019 to 08 Jan 2020)
13.600 14.320 9.700 13.000 905,032 -
4 Weeks from
(25 Nov 2019 to 23 Dec 2019)
12.850 13.833 9.700 13.560 3,360,608 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.